NCT06322147 2024-03-20
Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer
Qilu Hospital of Shandong University
Unknown
Clinical Trials
12 trialsNCT03914170 2023-09-26
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
Completed
NCT04673955 2022-09-29
BERING-CRC
Pierre Fabre Pharma GmbH
Recruiting
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT01310985 2019-03-01
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
King Faisal Specialist Hospital & Research Center
Completed
NCT03401957 2018-01-17
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
National Health Research Institutes, Taiwan
Unknown
NCT01134666 2017-06-09
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany
Terminated
NCT02994888 2016-12-19
PROSPECT-C
Royal Marsden NHS Foundation Trust
Completed
NCT01943786 2015-03-17
BEAMING
Grupo Hospital de Madrid
Unknown
NCT01082315 2014-08-29
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Completed
NCT01074333 2014-06-17
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Terminated
NCT00912327 2012-02-15
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
HiberCell, Inc.
Completed